Presage Biosciences is an oncology company that is pioneering an entirely novel approach to evaluating patient response to drugs in clinical trials.
Using our patented CIVO™ technology, we deliver pharmacologically appropriate concentrations of multiple drugs to different regions of a tumor – while the tumor is still in the patient. Observing molecular and cellular responses to drugs and combinations in an authentic human tumor gives us a far greater understanding of tumor biology, directly embodying a patient’s own immune system, tumor microenvironment, heterogeneity and genetic background. It is Presage’s mission to use this understanding to revolutionize the way drugs are selected, tested and targeted, with the goal of providing more effective treatments to patients with cancer.
Through research alliances, Presage collaborates with biopharmaceutical companies to discover new, effective drug combinations and to identify drug sensitivity and resistance in target patient populations. Presage also is actively developing in-licensed drug candidates and plans to employ CIVO™ to advance a portfolio of promising oncology therapies to the clinic.
Presage Biosciences Appoints David Johnson to Board of Directors
June 3, 2016 | Seattle, Wash. Presage Biosciences, an oncology company that is developing a novel drug development platform to assess drugs and combinations directly in patient tumors, announced today the appointment of David Johnson to its board of directors. Johnson has more than two decades of experience in the biopharmaceutical industry spanning operations, management, financing and therapeutics discovery and development.
Presage Biosciences Presents Data Demonstrating Tumor Growth Inhibition by Voruciclib and Proteasome Inhibitors Superior to Single Agents in Model of Triple Negative Breast Cancer
April 19, 2016 | Seattle, Wash. Presage Biosciences, an oncology company that is developing a novel drug development platform to assess drug combinations directly in patient tumors, will present preclinical data showing that the company’s clinical-stage oral CDK inhibitor, voruciclib, in combination with proteasome inhibitors, demonstrated superior tumor growth inhibition in xenografts than the single agents separately in a model of triple negative breast cancer (TNBC), a disease which has proven challenging to treat with standard chemotherapy options. The data are being presented today at the American Association for Cancer Research (AACR) 2016 Annual Meeting in New Orleans.